clinical trial · NCT07600450
A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive
Kidney DiseaseGSK4771261Placebo
brief summary
This is a first time in Asia (FTIA) study of GSK4771261 in healthy participants of Chinese, Japanese, and White/European ancestry. The study will test whether GSK4771261 is safe, well-tolerated, how it is processed in the body, and whether it triggers an immune response.
started
May 18, 2026
primary completion
May 20, 2027
completion
May 20, 2027
last updated
Oct 5, 2026
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacodynamics of GSK4771261 Administered as a Single Subcutaneous Dose to Healthy Participants of Chinese, Japanese and White/European Ancestry Aged 25 to 55 Years of Age Inclusive
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol